Simulations Plus: Q3 Earnings Insights

Shares of Simulations Plus SLP rose fell in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share fell 10.00% year over year to $0.18, which were in line with the estimate of $0.18.

Revenue of $12,777,000 up by 3.89% from the same period last year, which missed the estimate of $14,740,000.

Looking Ahead

Simulations Plus hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Jul 12, 2021

Time: 04:15 PM

ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1476598&tp_key=b27f3b466f

Price Action

Company's 52-week high was at $90.92

52-week low: $49.34

Price action over last quarter: down 12.39%

Company Profile

Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Simulations Plus, Inc; Cognigen Corporation; DILIsym, and Lixoft. It generates maximum revenue from Simulations Plus, Inc segment. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor which is a computer program that takes molecular structures as inputs; MedChem Designer and MedChem Studio.